Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

• Published in: NeuroImage (Orlando, Fla.) Vol. 51; no. 2; pp. 654 - 664
• Main Authors: Chen, Kewei, Langbaum, Jessica B.S., Fleisher, Adam S., Ayutyanont, Napatkamon, Reschke, Cole, Lee, Wendy, Liu, Xiaofen, Bandy, Dan, Alexander, Gene E., Thompson, Paul M., Foster, Norman L., Harvey, Danielle J., de Leon, Mony J., Koeppe, Robert A., Jagust, William J., Weiner, Michael W., Reiman, Eric M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2010; Elsevier Limited
• Subjects: Aged; Algorithms; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - pathology; Alzheimer's disease; Biomarkers; Brain - diagnostic imaging; Brain - pathology; Brain Mapping - methods; Clinical trials; Cognition Disorders - diagnostic imaging; Cognition Disorders - pathology; Cognitive ability; Disease Progression; Female; Humans; Longitudinal Studies; Male; Medical imaging; Multicenter Studies as Topic; Pathology; Positron-Emission Tomography; Randomized Controlled Trials as Topic; Research Design; Studies

Alzheimer's disease (AD) is characterized by specific and progressive reductions in fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the cerebral metabolic rate for glucose (CMRgl), some of which may precede the onset of symptoms. In this report, we describe twelve-mont...